A Phase 3 interventional study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC and DRV/COBI FDC in Immunodeficiency Virus Type 1, Human, sponsored by Janssen Sciences Ireland UC. Completed at 81 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-28.
Sponsored by Janssen Sciences Ireland UC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to demonstrate non-inferiority in efficacy of a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus Darunavir/Cobicistat (DRV/COBI) FDC coadministered with Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC in human immunodeficiency virus-1 (HIV-1) infected, antiretroviral (ARV) treatment naive adult participants.
This is a Phase 3, multicenter (when more than one hospital or medical school team work on a medical research study), randomized (study drug assigned by chance), double-blind (a medical research study in which neither the researchers nor the participant know what treatment the participant is receiving), active-controlled (study in which the experimental treatment or procedure is compared to a standard [control] treatment or procedure) study. The study consists of 5 periods: a Screening period, Double-blind treatment period, Single-arm treatment period, Extension period and a Follow-up period. Participants will receive either darunavir (DRV)/ cobicistat (COBI)/emtricitabine (FTC) /tenofovir alafenamide (TAF) fixed dose combination (D/C/F/TAF FDC) or DRV/COBI FDC along with FTC/TDF FDC. Primarily percentage of participants with human immunodeficiency virus (HIV) -1 Ribonucleic acid (RNA) less than (\<) 50 copies per milliliter (copies/ml) defined by snapshot analysis will be evaluated. Participants' safety will be monitored throughout the study.
3,037 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
This study's enrollment of 725 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →Janssen Sciences Ireland UC is the lead sponsor of 29 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject will receive a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination \[FDC\]) once daily along with DRV/COBI FDC-matching and FTC/TDF FDC-matching placebo tablets once daily up to Week 48 analysis unblinding visit (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding visit, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.
Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC · Drug: FTC/TDF FDC Matching Placebo · Drug: DRV/COBI FDC Matching Placebo
Subject will receive DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48 analysis unblinding (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.
Drug: DRV/COBI FDC · Drug: FTC/TDF FDC · Drug: D/C/F/TAF FDC - Matching Placebo
Drug pages: Darunavir · Cobicistat · Emtricitabine · Tenofovir alafenamide
A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.
A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
Drug pages: Emtricitabine · Tenofovir
A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
Matching placebo of D/C/F/TAF FDC will be administered once daily.
Matching placebo of FTC/TDF FDC will be administered once daily.
Matching placebo of DRV/COBI FDC will be administered once daily.
Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response) at Week 48 Defined by Food and Drug Administration (FDA) Snapshot Approach
Percentage of participants with a HIV-1 RNA \< 50 copies per mL were assessed using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA \< 20/50/200 copies per mL at Week 48), 2) virologic failure (HIV RNA greater than or equal to \[\>=\] 20/50/200 copies per mL at Week 48), 3) no viral load data in the Week 48 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.
Time frame: At Week 48
Percentage of Participants With HIV-1 RNA <20 and 200 Copies Per mL at Weeks 48 and 96 Defined by FDA Snapshot Approach
Percentage of participants with HIV-1 RNA \< 20/200 copies per mL using FDA snapshot approach were reported. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA \< 20/50/200 copies per mL at Week 48 and 96), 2) virologic failure (HIV RNA \>= 20/50/200 copies per mL at Week 48 and 96), 3) no viral load data in the Week 48 and 96 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.
Time frame: At Weeks 48 and 96
Percentage of Participants With HIV-1 RNA < 20, 50, and 200 Copies Per mL at Week 48 and 96 Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Percentage of participants with HIV-1 RNA less than (\<) 20, 50, and 200 copies per mL at Weeks 48 and 96 based on TLOVR algorithm were assessed. TLOVR requires sustained HIV-1 RNA \< 50 copies per mL; confirmed HIV-1 RNA \>= 50 copies per mL is considered as non-response (rebound); participant is considered non-responder after permanent discontinuation.
Time frame: At Week 48 and 96
Change From Baseline in log10 HIV-1 RNA Levels at Week 48
Change from baseline in log10 HIV-1 RNA levels were reported.
Time frame: Baseline and Week 48
Change From Baseline in Cluster of Differentiation-4 (CD4+) Cell Count at Week 48
The immunologic change was determined by changes in Cluster of CD4+ cell count. Change from baseline in CD4+ cell count at Week 48 were assessed.
Time frame: Baseline and Week 48
Change From Baseline in Serum Creatinine at Week 48
Change from baseline in serum creatinine at Week 48 was reported.
Time frame: Baseline and Week 48
Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula at Week 48
Change from baseline in eGFRcr was calculated using the CKD-EPI equation as per which Stage 1 (normal or high GFR \[\>=90 mL/min\]); Stage 2 (Mild CKD \[60 to 90 mL/min\]); Stage 3 (Moderate CKD \[30 to 59mL/min\]); Stage 4 (Severe CKD \[15 to 29 mL/min\]); Stage 5 (End Stage CKD \[\<15 mL/min\]). The eGFRcr was assessed by calculating serum creatinine (Scr) using the equation: eGFRcr milliliter per minute per 1.72 meter square (mL/min/1.73m\^2) = 144\*(Scr/0.7)\^-0.329\*0.993\^age (Scr =\< 0.7 mg/dL) and eGFRcr mL/min/1.73m\^2 = 144\*(Scr/0.7)\^-1.209\*0.993\^age (Scr \>0.7 mg/dL) for female participants and eGFRcr mL/min/1.73m\^2 = 141\*(Scr/0.9)\^-0.411\*0.993\^age (Scr =\<0.9 mg/dL) and eGFRcr mL/min/1.73m\^2 = 141\*(Scr/0.9)\^-1.209\*0.993\^age (Scr \>0.9 mg/dL) for male participants.
Time frame: Baseline and Week 48
Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine by (Cockcroft-Gault Formula) at Week 48
Change from baseline in eGFRcr by cockcroft-gault formula at Week 48. The eGFRcr was assessed by calculated creatinine clearance (CrCl) using the Cockcroft-Gault formula, and was assessed using CrCl \[mL/min\] = (140 - A) \* W / (72 \* C) \* R. Where A is age at sample date \[years\], W is body weight at specific visit (kilogram \[kg\]), C is the serum concentration of creatinine \[mg/dL\], R = 1 if the participant is male and = 0.85 if female.
Time frame: Baseline and Week 48
Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula at Week 48
Change from baseline in eGFRcyst was calculated using the CKD-EPI equation as per which Stage 1 (normal or high GFR) \>= 90 indicates normal kidney function; Stage 2 (Mild CKD): 60 to 89 mL/min indicates mildly reduced kidney function; Stage 3 (Moderate CKD): 30 to 59 mL/min indicates moderately reduced kidney function; Stage 4 (Severe CKD): 15 to 29 mL/min indicates severely reduced kidney function; Stage 5 (End Stage of CKD): \<15 mL/min indicate very severe or end stage kidney failure. The eGFRcyst was assessed by calculated serum cystatin C (Scyst) using the equation: eGFRcyst mL/min/1.73m\^2 = 133 \* (Scyst/0,8)\^-0.499 \* 0.996\^age \[\* 0.932 if female\] (Scyst =\<0.8 mg/L) and eGFRcr mL/min/1.73m\^2 = 133 \* (Scyst/0,8)\^-1.328 \* 0.996\^age \[\* 0.932 if male\] (Scyst \>0.8 mg/L).
Time frame: Baseline and Week 48
Percentage of Participants With Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuations Due to Adverse Events Through Week 48
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
Time frame: Up to Weeks 48
Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48
Change from baseline in UPCR at Week 48 was reported.
Time frame: Baseline and Week 48
Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) at Week 48
Change from baseline in UACR at Week 48 was reported.
Time frame: Baseline and Week 48
Change From Baseline in Urine Retinol Binding Protein To Creatinine Ratio (URBPCR) at Week 48
Change from baseline in URBPCR at Week 48 were reported.
Time frame: Baseline and Week 48
Change From Baseline in Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Week 48
Change from baseline in UB2MGCR at Week 48 were reported.
Time frame: Baseline and Week 48
Percent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Week 48
Percent change from baseline in FEPO4 at Week 48 was reported.
Time frame: Baseline and Week 48
Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC0-24h) of Darunavir
AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours post-dose.
Time frame: 0 to 24 hours post dose
Predose (Trough) Plasma Concentration (C0h) of Darunavir
C0h is defined as the predose (trough) plasma concentration or concentration just prior to study drug administration.
Time frame: 30 minutes to 4 hours postdose at Weeks 2, 4, 12, 24 and 48 and at 2 timepoints with at least 2.5 hours in between sampling at Week 8 and 36 (first sample between 1 and 4 hours postdose)
Area Under the Plasma Concentration Time Curve Across the Dosing Interval (AUCtau) of Tenofovir Alafenamide
The AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval. It is used to characterize drug absorption.
Time frame: 30 minutes to 4 hours postdose at Weeks 2, 4, 12, 24 and 48 and at 2 timepoints with at least 2.5 hours in between sampling at Week 8 and 36 (first sample between 1 and 4 hours postdose)
Plasma Concentrations 2 Hours After Dosing (C0-2h) of Tenofovir Alafenamide
C0-2h is defined as the plasma concentrations 2 hours after dosing.
Time frame: 0 to 2 hours post dose
Percent Change From Baseline in Hip and Spine Bone Mineral Density (BMD)
The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by dual energy x-ray absorptiometry (DEXA) scan. Positive values are "best values" and negative values are "worst values" of change. Percent change from baseline in hip and spine BMD was assessed.
Time frame: Baseline, Weeks 24 and 48
Change From Baseline in BMD T-score of Hip and Spine
BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score \>= -1, osteopenia by a T-score \>= -2.5 to \<-1.0, and osteoporosis by a T-score \<-2.5.
Time frame: Baseline, Weeks 24 and 48
Change From Baseline in Alkaline Phosphatase (ALP) Levels at Weeks 24 and 48
Change from baseline in ALP at Weeks 24 and 48 was reported.
Time frame: Baseline, Weeks 24 and 48
Change From Baseline in Levels of Serum Procollagen 1 N-Terminal Propeptide (P1NP) at Weeks 24 and 48
Change from baseline in serum P1NP at Weeks 24 and 48 were reported.
Time frame: Baseline, Weeks 24 and 48
Change From Baseline in Levels of Serum Collagen Type 1 Beta Carboxy Telopeptide (CTX) at Weeks 24 and 48
Change from baseline in serum CTX at Weeks 24 and 48 were reported.
Time frame: Baseline, Weeks 24 and 48
Change From Baseline in Levels of Parathyroid Hormone (PTH) at Weeks 24 and 48
Change from baseline in PTH at Weeks 24 and 48 were reported.
Time frame: Baseline, Weeks 24 and 48
Change From Baseline in Levels of 25-Hydroxyvitamin D (25-OH Vitamin D), at Week 24 and 48
Change from baseline in 25-OH Vitamin D levels at Week 24 and 48 were reported.
Time frame: Baseline, Weeks 24 and 48
Percentage of Participants With HIV-1 RNA <50 Copies Per mL at Week 96 Defined by FDA Snapshot Approach
Percentage of participants with a HIV-1 RNA \< 50 copies per mL were assessed using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA \< 20/50/200 copies per mL at Week 96), 2) virologic failure (HIV RNA greater than or equal to \[\>=\] 20/50/200 copies per mL at Week 96), 3) no viral load data in the Week 96 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.
Time frame: At Week 96
Change From Reference in log10 HIV-1 RNA Levels at Week 96
Change from reference in log10 HIV-1 RNA levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for Test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in CD4+ Cell Count at Week 96
The immunologic change was determined by changes in cluster of differentiation (CD4+) cell count. Change from reference in CD4+ cell count at Week 96 was assessed. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Percentage of Participants With >95% Treatment Adherence Assessed by Drug Accountability
Treatment adherence assessed by drug accountability (based on pill count) from start of treatment/switch to last study drug intake by determination of the cumulative treatment adherence in participants who returned all dispensed bottles prior to or at the last visit in the study. Adherent participants were defined as having an adherence \>95% as assessed by drug accountability.
Time frame: Baseline to Switch and switch to EOE to Open-Label D/C/F/TAF (Up to 3 years)
Percentage of Participants With Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuations Due to Adverse Events Through Week 96
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
Time frame: Up to Week 96
Change From Reference in Serum Creatinine
Change from reference in serum creatinine was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in eGFRcr by CKD-EPI Formula
Change from reference in eGFRcr was calculated using the CKD-EPI equation as per Stage 1 (normal or high GFR) to Stage 5 (End Stage of CKD). The eGFRcr was assessed by calculating serum creatinine (Scr) using the CKD-EPI equation: eGFRcr milliliter per minute per 1.72 meter square (mL/min/1.73m\^2) = 144 \* (Scr/0.7)\^-0.329 \* 0.993\^age (Scr =\< 0.7 mg/dL) and eGFRcr mL/min/1.73m\^2 = 144 \* (Scr/0.7)\^-1.209 \* 0.993\^age (Scr \>0.7 mg/dL) for female participants and eGFRcr mL/min/1.73m\^2 = 141 x (Scr/0.9)\^-0.411 x 0.993\^age (Scr =\<0.9 mg/dL) and eGFRcr mL/min/1.73m\^2 = 141 \* (Scr/0.9)\^-1.209 x 0.993\^age (Scr \>0.9 mg/dL) for male participants. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine by Cockcroft-Gault Formula
Change from reference in eGFRcr by cockcroft-gault formula was reported. The eGFRcr was assessed by calculated creatinine clearance (CrCl) using the Cockcroft-Gault formula, and was assessed using CrCl \[mL/min\] = (140 - A) \* W / (72 \* C) \* R. Where A is age at sample date \[years\], W is body weight at specific visit (kilogram \[kg\]), C is the serum concentration of creatinine \[mg/dL\], R = 1 if the participant is male and = 0.85 if female. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula
Change from reference in eGFRcyst was calculated using the CKD-EPI equation as per Stage 1 (normal or high GFR) to Stage 5 (End Stage of CKD): \<15 mL/min indicate very severe or end stage kidney failure. The eGFRcyst was assessed by calculated serum cystatin C (Scyst) using the CKD-EPI equation: eGFRcyst mL/min/1.73m\^2 = 133 \* (Scyst/0,8)\^-0.499 \* 0.996\^age \[x 0.932 if female\] (Scyst =\<0.8 mg/L) and eGFRcr mL/min/1.73m\^2 = 133 \* (Scyst/0,8)\^-1.328 \* 0.996\^age \[\* 0.932 if male\] (Scyst \>0.8 mg/L). Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in UPCR
Change from reference in UPCR was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in UACR
Change from reference in UACR at Week 96 was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in URBPCR
Change from reference in URBPCR at Week 96 were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in UB2MGCR
Change from reference in UB2MGCR was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Percent Change From Reference in Urine FEPO4
Percent change from reference in FEPO4 at Week 96 were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Percent Change From Reference in Hip and Spine BMD
The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by DEXA scan. Positive values are "best values" and negative values are "worst values" of change. Percent change from reference in hip and spine BMD was assessed. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in BMD T-score of Hip and Spine at Week 96
BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score \>= -1, osteopenia by a T-score \>= -2.5 to \<-1.0, and osteoporosis by a T-score \<-2.5. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in ALP Levels
Change from reference in ALP levels at Week 96 was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in Levels of Serum P1NP
Change from reference in serum P1NP levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in Levels of Serum CTX
Change from reference in serum CTX levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in Levels of PTH
Change from reference in PTH levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Change From Reference in Levels of 25-OH Vitamin D
Change from reference in 25-OH Vitamin D were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
Time frame: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Percentage of Participants With HIV RNA <50, <20, and <200 Copies/mL Post-week 96 to End of Extension
Percentage of participants with HIV RNA \<50, \<20, and \<200 copies/mL post Week 96 to end of extension were reported.
Time frame: Week 96 to end of extension (up to 3 years)
Percentage of Participants With Protocol-defined Virologic Failure (PDVF)
Percentage of participants with PDVF were reported. Protocol-defined virologic failure was defined as having virologic non-response (HIV-1 RNA \<1 log10 reduction from baseline and \>=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA \>=50 copies/mL after confirmed consecutive HIV-1 RNA \<50 copies/mL or confirmed \>1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA \>=400 copies/mL).
Time frame: From Baseline up to Week 96
Percentage of Participants With PDVF Post-week 96 to End of Extension
Percentage of participants with PDVF were reported. Protocol-defined virologic failure was defined as having virologic non-response (HIV-1 RNA \<1 log10 reduction from baseline and \>=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA \>=50 copies/mL after confirmed consecutive HIV-1 RNA \<50 copies/mL or confirmed \>1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA \>=400 copies/mL).
Time frame: Week 96 to end of extension (up to 3 years)
Percentage of Participants With Non-PDVF by Kaplan-Meier Estimates
Percentage of participants with non-PDVF by Kaplan-Meier Estimates were reported. PDVF was defined as having virologic non-response (HIV-1 RNA \<1 log10 reduction from baseline and \>=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA \>=50 copies/mL after confirmed consecutive HIV-1 RNA \<50 copies/mL or confirmed \>1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA \>=400 copies/mL).
Time frame: From Week 96 to end of extension (up to 2 years and 6 months)
Percentage of Participants With Time to Treatment Failure by Kaplan-Meier Estimates
Percentage of participants with time to treatment failure by Kaplan-Meier Estimates were reported. Treatment failure was defined as having either protocol-defined virologic failure or having discontinued for reasons other than alternate access to D/C/F/TAF (or other ARVs).
Time frame: From Week 96 to end of extension (up to 3 years)
CD4+ Cell Count Post-Week From 96 to End of Extension
The immunologic change was determined by Cluster of CD4+ cell count. CD4+ cell count post-Week 96 to end of extension were assessed.
Time frame: Week 96 to end of extension (up to 3 years)
Number of Participants With ARV Resistance
Number of participants with DRV, FTC, TDF/TAF resistance were reported.
Time frame: Baseline to end of extension (up to 4 years)
Percentage of Participants With Grade 3 and 4 AEs, SAEs, and Premature Discontinuations Due to Adverse Events Post-Week 96 to End of Extension
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
Time frame: From Week 96 to end of extension (up to 3 years)
| Milestone | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | Switch to D/C/F/TAF |
|---|---|---|---|
| Started | 362 | 363 | 0 |
| Completed | 296 | 322 | 0 |
| Not completed | 66 | 41 | 0 |
| Withdrew: Other | 11 | 2 | 0 |
| Withdrew: Lost to follow-up | 17 | 8 | 0 |
| Withdrew: Physician decision | 9 | 4 | 0 |
| Withdrew: Pregnancy | 1 | 1 | 0 |
| Withdrew: Adverse event | 12 | 16 | 0 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 14 | 9 | 0 |
| Withdrew: Subject non-compliant | 2 | 0 | 0 |
| Milestone | D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | Switch to D/C/F/TAF |
|---|---|---|---|
| Started | 0 | 0 | 322 |
| Completed | 0 | 0 | 289 |
| Not completed | 0 | 0 | 33 |
| Withdrew: Other | 0 | 0 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 12 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 5 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 10 |
Percentage of participants with a HIV-1 RNA \< 50 copies per mL were assessed using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA \< 20/50/200 copies per mL at Week 48), 2) virologic failure (HIV RNA greater than or equal to \[\>=\] 20/50/200 copies per mL at Week 48), 3) no viral load data in the Week 48 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.
| percentage of participants | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response) at Week 48 Defined by Food and Drug Administration (FDA) Snapshot Approach | 91.4 ± 88.1 | 88.4 ± 84.7 |
Percentage of participants with HIV-1 RNA \< 20/200 copies per mL using FDA snapshot approach were reported. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA \< 20/50/200 copies per mL at Week 48 and 96), 2) virologic failure (HIV RNA \>= 20/50/200 copies per mL at Week 48 and 96), 3) no viral load data in the Week 48 and 96 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.
| percentage of participants | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | Switch to D/C/F/TAF |
|---|---|---|---|
| At week 48: <20 Copies per mL | 82.6 (78.3 to 86.4) | 79.3 (74.8 to 83.4) | — |
| At week 48: <200 Copies per mL | 92.8 (89.7 to 95.3) | 90.6 (87.2 to 93.4) | — |
| At week 96: <20 Copies per mL | 76.2 (71.5 to 80.5) | — | 83.5 (78.7 to 87.6) |
| At week 96: <200 Copies per mL | 86.2 (82.2 to 89.6) | — | 96.9 (94.2 to 98.6) |
Percentage of participants with HIV-1 RNA less than (\<) 20, 50, and 200 copies per mL at Weeks 48 and 96 based on TLOVR algorithm were assessed. TLOVR requires sustained HIV-1 RNA \< 50 copies per mL; confirmed HIV-1 RNA \>= 50 copies per mL is considered as non-response (rebound); participant is considered non-responder after permanent discontinuation.
| percentage of participants | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | Switch to D/C/F/TAF |
|---|---|---|---|
| At Week 48: < 20 Copies per mL | 82.6 (78.3 to 86.4) | 79.9 (75.4 to 83.9) | — |
| At Week 48: <50 Copies per mL | 91.2 (87.8 to 93.9) | 88.7 (85.0 to 91.8) | — |
| At Week 48: <200 Copies per mL | 93.1 (90.0 to 95.5) | 91.7 (88.4 to 94.4) | — |
| At Week 96: <20 Copies per mL | 73.2 (68.3 to 77.7) | — | 78.4 (73.2 to 82.9) |
| At Week 96: <50 Copies per mL | 85.1 (81.0 to 88.6) | — | 93.8 (90.4 to 96.3) |
| At Week 96: <200 Copies per mL | 86.7 (82.8 to 90.1) | — | 96.9 (94.2 to 98.6) |
Change from baseline in log10 HIV-1 RNA levels were reported.
| log10 HIV-1 RNA copies per mL | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Change From Baseline in log10 HIV-1 RNA Levels at Week 48 | -2.95 ± 0.044 | -2.91 ± 0.044 |
The immunologic change was determined by changes in Cluster of CD4+ cell count. Change from baseline in CD4+ cell count at Week 48 were assessed.
| Cells per millimeter cube (cells/mm^3) | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Change From Baseline in Cluster of Differentiation-4 (CD4+) Cell Count at Week 48 | 190.49 ± 10.472 | 172.01 ± 10.458 |
Change from baseline in serum creatinine at Week 48 was reported.
| milligram per deciliter (mg/dL) | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Change From Baseline in Serum Creatinine at Week 48 | 0.05 ± 0.006 | 0.09 ± 0.006 |
Change from baseline in eGFRcr was calculated using the CKD-EPI equation as per which Stage 1 (normal or high GFR \[\>=90 mL/min\]); Stage 2 (Mild CKD \[60 to 90 mL/min\]); Stage 3 (Moderate CKD \[30 to 59mL/min\]); Stage 4 (Severe CKD \[15 to 29 mL/min\]); Stage 5 (End Stage CKD \[\<15 mL/min\]). The eGFRcr was assessed by calculating serum creatinine (Scr) using the equation: eGFRcr milliliter per minute per 1.72 meter square (mL/min/1.73m\^2) = 144\*(Scr/0.7)\^-0.329\*0.993\^age (Scr =\< 0.7 mg/dL) and eGFRcr mL/min/1.73m\^2 = 144\*(Scr/0.7)\^-1.209\*0.993\^age (Scr \>0.7 mg/dL) for female participants and eGFRcr mL/min/1.73m\^2 = 141\*(Scr/0.9)\^-0.411\*0.993\^age (Scr =\<0.9 mg/dL) and eGFRcr mL/min/1.73m\^2 = 141\*(Scr/0.9)\^-1.209\*0.993\^age (Scr \>0.9 mg/dL) for male participants.
| mL/min/1.73 m^2 | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula at Week 48 | -6.04 ± 0.551 | -9.16 ± 0.559 |
Change from baseline in eGFRcr by cockcroft-gault formula at Week 48. The eGFRcr was assessed by calculated creatinine clearance (CrCl) using the Cockcroft-Gault formula, and was assessed using CrCl \[mL/min\] = (140 - A) \* W / (72 \* C) \* R. Where A is age at sample date \[years\], W is body weight at specific visit (kilogram \[kg\]), C is the serum concentration of creatinine \[mg/dL\], R = 1 if the participant is male and = 0.85 if female.
| milliliter per minute (mL/min) | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine by (Cockcroft-Gault Formula) at Week 48 | -5.16 ± 0.790 | -11.20 ± 0.802 |
Change from baseline in eGFRcyst was calculated using the CKD-EPI equation as per which Stage 1 (normal or high GFR) \>= 90 indicates normal kidney function; Stage 2 (Mild CKD): 60 to 89 mL/min indicates mildly reduced kidney function; Stage 3 (Moderate CKD): 30 to 59 mL/min indicates moderately reduced kidney function; Stage 4 (Severe CKD): 15 to 29 mL/min indicates severely reduced kidney function; Stage 5 (End Stage of CKD): \<15 mL/min indicate very severe or end stage kidney failure. The eGFRcyst was assessed by calculated serum cystatin C (Scyst) using the equation: eGFRcyst mL/min/1.73m\^2 = 133 \* (Scyst/0,8)\^-0.499 \* 0.996\^age \[\* 0.932 if female\] (Scyst =\<0.8 mg/L) and eGFRcr mL/min/1.73m\^2 = 133 \* (Scyst/0,8)\^-1.328 \* 0.996\^age \[\* 0.932 if male\] (Scyst \>0.8 mg/L).
| mL/min/1.73 m^2 | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula at Week 48 | 5.32 ± 0.525 | 2.92 ± 0.532 |
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
| percentage of participants | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Grade 3 AEs | 4.7 | 4.4 |
| Grade 4 AEs | 0.6 | 1.7 |
| SAEs | 4.7 | 5.8 |
| Premature discontinuations due to AEs | 1.9 | 4.4 |
Change from baseline in UPCR at Week 48 was reported.
| milligram per gram (mg/g) | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48 | -15.72 ± -748.1 | -10.53 ± -903.0 |
Change from baseline in UACR at Week 48 was reported.
| mg/g | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) at Week 48 | -0.58 ± -226.5 | -0.15 ± -640.4 |
Change from baseline in URBPCR at Week 48 were reported.
| microgram per gram (mcg/g) | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Change From Baseline in Urine Retinol Binding Protein To Creatinine Ratio (URBPCR) at Week 48 | 7.00 ± -1555.7 | 35.02 ± -700.7 |
Change from baseline in UB2MGCR at Week 48 were reported.
| mcg/g | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Change From Baseline in Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Week 48 | -30.42 ± -11818.6 | 18.36 ± -2440.5 |
Percent change from baseline in FEPO4 at Week 48 was reported.
| Percent change | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Percent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Week 48 | 16.00 ± -87.3 | 22.55 ± -90.1 |
AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours post-dose.
| hours*nanogram per milliliter (h*ng/mL) | Darunavir 800 mg [D/C/F/TAF] |
|---|---|
| Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC0-24h) of Darunavir | 87909.3282 ± 20232.09905 |
C0h is defined as the predose (trough) plasma concentration or concentration just prior to study drug administration.
| nanogram per milliliter (ng/mL) | Darunavir 800 mg [D/C/F/TAF (Test)] |
|---|---|
| Predose (Trough) Plasma Concentration (C0h) of Darunavir | 1898.9100 ± 758.83837 |
The AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval. It is used to characterize drug absorption.
| h*ng/mL | Tenofovir Alafenamide 10 mg [D/C/F/TAF (Test)] |
|---|---|
| Area Under the Plasma Concentration Time Curve Across the Dosing Interval (AUCtau) of Tenofovir Alafenamide | 132.3117 ± 40.87742 |
C0-2h is defined as the plasma concentrations 2 hours after dosing.
| ng/mL | Tenofovir Alafenamide 10 mg [D/C/F/TAF (Test)] |
|---|---|
| Plasma Concentrations 2 Hours After Dosing (C0-2h) of Tenofovir Alafenamide | 11.9785 ± 11.86104 |
The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by dual energy x-ray absorptiometry (DEXA) scan. Positive values are "best values" and negative values are "worst values" of change. Percent change from baseline in hip and spine BMD was assessed.
| Percent change | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Hip region BMD (Week 24) | 0.29 ± 0.248 | -1.66 ± 0.269 |
| Spine region BMD (Week 24) | -1.34 ± 0.285 | -3.43 ± 0.309 |
| Hip region BMD (Week 48) | 0.17 ± 0.322 | -2.69 ± 0.342 |
| Spine region BMD (Week 48) | -0.68 ± 0.402 | -2.38 ± 0.428 |
BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score \>= -1, osteopenia by a T-score \>= -2.5 to \<-1.0, and osteoporosis by a T-score \<-2.5.
| BMD T-score | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Hip region BMD T-score (Week 24) | 0.019 ± 0.0180 | -0.109 ± 0.0157 |
| Spine region BMD T-score (Week 24) | -0.121 ± 0.0259 | -0.322 ± 0.0307 |
| Hip region BMD T-score (Week 48) | 0.015 ± 0.0213 | -0.177 ± 0.0225 |
| Spine region BMD T-score (Week 48) | -0.061 ± 0.0390 | -0.225 ± 0.0386 |
Change from baseline in ALP at Weeks 24 and 48 was reported.
| Units per liter (U/L) | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Week 24 | -3.2 ± 1.17 | 12.0 ± 1.74 |
| Week 48 | -1.1 ± 1.29 | 15.1 ± 2.00 |
Change from baseline in serum P1NP at Weeks 24 and 48 were reported.
| microgram per liter (mcg/L) | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Week 24 | 1.892 ± 1.3754 | 24.679 ± 2.0956 |
| Week 48 | 0.065 ± 1.6428 | 24.251 ± 2.6337 |
Change from baseline in serum CTX at Weeks 24 and 48 were reported.
| mcg/L | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Week 24 | 0.047 ± 0.0165 | 0.283 ± 0.0251 |
| Week 48 | 0.046 ± 0.0174 | 0.226 ± 0.0234 |
Change from baseline in PTH at Weeks 24 and 48 were reported.
| Picomol per liter (pmol/L) | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Week 24 | 0.113 ± 0.2171 | 0.777 ± 0.2401 |
| Week 48 | -0.004 ± 0.2232 | 0.633 ± 0.2155 |
Change from baseline in 25-OH Vitamin D levels at Week 24 and 48 were reported.
| nanomol per liter (nmol/L) | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) |
|---|---|---|
| Week 24 | 12.7 ± 2.76 | 22.1 ± 3.76 |
| Week 48 | 16.9 ± 2.84 | 28.3 ± 3.15 |
Percentage of participants with a HIV-1 RNA \< 50 copies per mL were assessed using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA \< 20/50/200 copies per mL at Week 96), 2) virologic failure (HIV RNA greater than or equal to \[\>=\] 20/50/200 copies per mL at Week 96), 3) no viral load data in the Week 96 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.
| percentage of participants | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <50 Copies Per mL at Week 96 Defined by FDA Snapshot Approach | 85.1 ± 81.0 | 94.2 ± 90.8 |
Change from reference in log10 HIV-1 RNA levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for Test group and reference 2 is the last value prior to the switch for Control group.
| log10 HIV-1 RNA copies per mL | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in log10 HIV-1 RNA Levels at Week 96 | -2.72 ± 0.0614 | -0.0027 ± 0.0131 |
The immunologic change was determined by changes in cluster of differentiation (CD4+) cell count. Change from reference in CD4+ cell count at Week 96 was assessed. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| cells/mm^3 | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in CD4+ Cell Count at Week 96 | 228.85 ± 11.951 | 27.01 ± 9.522 |
Treatment adherence assessed by drug accountability (based on pill count) from start of treatment/switch to last study drug intake by determination of the cumulative treatment adherence in participants who returned all dispensed bottles prior to or at the last visit in the study. Adherent participants were defined as having an adherence \>95% as assessed by drug accountability.
| percentage of participants | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | Switch to D/C/F/TAF |
|---|---|---|---|
| Baseline to Switch (double-blind treatment) | 87.2 | 82.6 | — |
| Switch to End of Extension (open-label D/C/F/TAF) | 92.2 | — | 88.7 |
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
| percentage of participants | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Grade 3 AEs | 11.6 | 3.7 |
| Grade 4 AEs | 0.8 | 1.4 |
| SAEs | 10.8 | 2.7 |
| Premature discontinuations due to AEs | 2.8 | 0.3 |
Change from reference in serum creatinine was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| mg/dL | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in Serum Creatinine | 0.045 ± -0.25 | -0.034 ± -0.71 |
Change from reference in eGFRcr was calculated using the CKD-EPI equation as per Stage 1 (normal or high GFR) to Stage 5 (End Stage of CKD). The eGFRcr was assessed by calculating serum creatinine (Scr) using the CKD-EPI equation: eGFRcr milliliter per minute per 1.72 meter square (mL/min/1.73m\^2) = 144 \* (Scr/0.7)\^-0.329 \* 0.993\^age (Scr =\< 0.7 mg/dL) and eGFRcr mL/min/1.73m\^2 = 144 \* (Scr/0.7)\^-1.209 \* 0.993\^age (Scr \>0.7 mg/dL) for female participants and eGFRcr mL/min/1.73m\^2 = 141 x (Scr/0.9)\^-0.411 x 0.993\^age (Scr =\<0.9 mg/dL) and eGFRcr mL/min/1.73m\^2 = 141 \* (Scr/0.9)\^-1.209 x 0.993\^age (Scr \>0.9 mg/dL) for male participants. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| mL/min/1.73 m^2 | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in eGFRcr by CKD-EPI Formula | -5.6 ± -33 | 2.3 ± -29 |
Change from reference in eGFRcr by cockcroft-gault formula was reported. The eGFRcr was assessed by calculated creatinine clearance (CrCl) using the Cockcroft-Gault formula, and was assessed using CrCl \[mL/min\] = (140 - A) \* W / (72 \* C) \* R. Where A is age at sample date \[years\], W is body weight at specific visit (kilogram \[kg\]), C is the serum concentration of creatinine \[mg/dL\], R = 1 if the participant is male and = 0.85 if female. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| mL/min | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine by Cockcroft-Gault Formula | -5.2 ± -73 | 4.6 ± -47 |
Change from reference in eGFRcyst was calculated using the CKD-EPI equation as per Stage 1 (normal or high GFR) to Stage 5 (End Stage of CKD): \<15 mL/min indicate very severe or end stage kidney failure. The eGFRcyst was assessed by calculated serum cystatin C (Scyst) using the CKD-EPI equation: eGFRcyst mL/min/1.73m\^2 = 133 \* (Scyst/0,8)\^-0.499 \* 0.996\^age \[x 0.932 if female\] (Scyst =\<0.8 mg/L) and eGFRcr mL/min/1.73m\^2 = 133 \* (Scyst/0,8)\^-1.328 \* 0.996\^age \[\* 0.932 if male\] (Scyst \>0.8 mg/L). Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| mL/min/1.73 m^2 | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula | 4.4 ± -14 | 0 ± -12 |
Change from reference in UPCR was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| mg/g | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in UPCR | -15.46 (-728.7 to 197.9) | -1.40 (-705.7 to 289.2) |
Change from reference in UACR at Week 96 was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| mg/g | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in UACR | -0.70 ± -288.1 | -0.49 ± -294.5 |
Change from reference in URBPCR at Week 96 were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| mcg/g | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in URBPCR | 13.70 ± -1555.1 | -35.53 ± -108886.3 |
Change from reference in UB2MGCR was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| mcg/g | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in UB2MGCR | -27.04 ± -11704.6 | -40.53 ± -111778.9 |
Percent change from reference in FEPO4 at Week 96 were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| Percent change in urine FEPO4 | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Percent Change From Reference in Urine FEPO4 | 18.52 ± -84.2 | -7.51 ± -83.5 |
The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by DEXA scan. Positive values are "best values" and negative values are "worst values" of change. Percent change from reference in hip and spine BMD was assessed. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| Percent change in BMD | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Hip region BMD | -0.2565 ± 0.35599 | 0.5467 ± 0.38512 |
| Spine region BMD | -0.9349 ± 0.44599 | 0.4829 ± 0.39270 |
BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score \>= -1, osteopenia by a T-score \>= -2.5 to \<-1.0, and osteoporosis by a T-score \<-2.5. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| BMD T-score | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Hip region BMD T-score | -0.016 ± 0.0245 | 0.025 ± 0.0272 |
| Spine region BMD T-score | -0.090 ± 0.0407 | 0.034 ± 0.0355 |
Change from reference in ALP levels at Week 96 was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| U/L | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in ALP Levels | -0.9 ± 1.23 | -9.7 ± 1.55 |
Change from reference in serum P1NP levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| mcg/L | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in Levels of Serum P1NP | 2.817 ± 1.7140 | -11.963 ± 1.7636 |
Change from reference in serum CTX levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| mcg/L | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in Levels of Serum CTX | 0.041 ± 0.0190 | -0.162 ± 0.0190 |
Change from reference in PTH levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| pmol/L | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in Levels of PTH | -0.290 ± 0.2078 | -1.283 ± 0.2483 |
Change from reference in 25-OH Vitamin D were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group.
| nmol/L | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Change From Reference in Levels of 25-OH Vitamin D | 21.3 ± 2.45 | -10.3 ± 2.87 |
Percentage of participants with HIV RNA \<50, \<20, and \<200 copies/mL post Week 96 to end of extension were reported.
| percentage of participants | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Week 96 + 6 months (<50 copies/mL) | 97.7 (95.3 to 99.1) | 96.3 (93.4 to 98.1) |
| Week 96 + 12 months (<50 copies/mL) | 99.0 (96.3 to 99.9) | 96.7 (93.4 to 98.7) |
| Week 96 + 18 months (<50 copies/mL) | 98.1 (94.6 to 99.6) | 98.2 (94.8 to 99.6) |
| Week 96 + 24 months (<50 copies/mL) | 97.5 (91.4 to 99.7) | 95.7 (89.2 to 98.8) |
| Week 96 + 30 months (<50 copies/mL) | 94.7 (85.4 to 98.9) | 91.4 (81.0 to 97.1) |
| Week 96 + 36 months (<50 copies/mL) | 100.0 (82.4 to 100.0) | 68.8 (41.3 to 89.0) |
| Week 96 + 6 months (<20 copies/mL) | 85.8 (81.4 to 89.5) | 88.2 (83.9 to 91.6) |
| Week 96 + 12 months (<20 copies/mL) | 89.7 (84.5 to 93.6) | 91.6 (87.0 to 94.9) |
| Week 96 + 18 months (<20 copies/mL) | 92.4 (87.1 to 96.0) | 92.8 (87.8 to 96.2) |
| Week 96 + 24 months (<20 copies/mL) | 90.1 (81.5 to 95.6) | 87.0 (78.3 to 93.1) |
| Week 96 + 30 months (<20 copies/mL) | 89.5 (78.5 to 96.0) | 84.5 (72.6 to 92.7) |
| Week 96 + 36 months (<20 copies/mL) | 94.7 (74.0 to 99.9) | 62.5 (35.4 to 84.8) |
| Week 96 + 6 months (<200 copies/mL) | 99.7 (98.2 to 100.0) | 99.3 (97.6 to 99.9) |
| Week 96 + 12 months (<200 copies/mL) | 100.0 (98.1 to 100.0) | 99.5 (97.4 to 100) |
| Week 96 + 18 months (<200 copies/mL) | 98.7 (95.5 to 99.8) | 98.2 (94.8 to 99.6) |
| Week 96 + 24 months (<200 copies/mL) | 97.5 (91.4 to 99.7) | 97.8 (92.4 to 99.7) |
| Week 96 + 30 months (<200 copies/mL) | 96.5 (87.9 to 99.6) | 98.3 (90.8 to 100.0) |
| Week 96 + 36 months (<200 copies/mL) | 100.0 (82.4 to 100.0) | 87.5 (61.7 to 98.4) |
Percentage of participants with PDVF were reported. Protocol-defined virologic failure was defined as having virologic non-response (HIV-1 RNA \<1 log10 reduction from baseline and \>=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA \>=50 copies/mL after confirmed consecutive HIV-1 RNA \<50 copies/mL or confirmed \>1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA \>=400 copies/mL).
| percentage of participants | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | Switch to D/C/F/TAF |
|---|---|---|---|
| Participants who met PDVF (Baseline - Week 96) | 4.1 | — | — |
| Virologic non-response (Baseline - Week 96) | 0.6 | — | — |
| Virologic rebound (Baseline-Week 96) | 0.3 | — | — |
| Viremic at final time point (Baseline-Week 96) | 0.6 | — | — |
| Participants who met PDVF (Baseline - Switch) | — | 4.4 | — |
| Virologic non-response (Baseline - Switch) | — | 0 | — |
| Virologic rebound (Baseline - Switch) | — | 3.9 | — |
| Viremic at final time point (Baseline - Switch) | — | 0.6 | — |
| Participants who met PDVF (Switch - Week 96) | — | — | 1.1 |
| Virologic non-response (Switch - Week 96) | — | — | 0 |
| Virologic rebound (Switch - Week 96) | — | — | 1.1 |
| Viremic at final time point (Switch - Week 96) | — | — | 0 |
Percentage of participants with PDVF were reported. Protocol-defined virologic failure was defined as having virologic non-response (HIV-1 RNA \<1 log10 reduction from baseline and \>=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA \>=50 copies/mL after confirmed consecutive HIV-1 RNA \<50 copies/mL or confirmed \>1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA \>=400 copies/mL).
| percentage of participants | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Participants who met PDVF | 1.0 | 2.1 |
| Virologic non-response | 0 | 0 |
| Virologic rebound | 1.0 | 1.4 |
| Viremic at final time point | 0 | 0.7 |
Percentage of participants with non-PDVF by Kaplan-Meier Estimates were reported. PDVF was defined as having virologic non-response (HIV-1 RNA \<1 log10 reduction from baseline and \>=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA \>=50 copies/mL after confirmed consecutive HIV-1 RNA \<50 copies/mL or confirmed \>1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA \>=400 copies/mL).
| percentage of participants | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Week 96 | 100 (100 to 100) | 100 (100 to 100) |
| Week 96 + 6 months | 99.6 (97.2 to 99.9) | 99.2 (97.0 to 99.8) |
| Week 96 + 12 months | 99.6 (97.2 to 99.9) | 99.2 (97.0 to 99.8) |
| Week 96 + 18 months | 98.6 (94.0 to 99.7) | 97.8 (94.1 to 99.2) |
| Week 96 + 24 months | 97.3 (91.0 to 99.2) | 97.8 (94.1 to 99.2) |
| Week 96 + 30 months | 97.3 (91.0 to 99.2) | 92.5 (79.8 to 97.3) |
Percentage of participants with time to treatment failure by Kaplan-Meier Estimates were reported. Treatment failure was defined as having either protocol-defined virologic failure or having discontinued for reasons other than alternate access to D/C/F/TAF (or other ARVs).
| percentage of participants | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Week 96 | 100 (100 to 100) | 100 (100 to 100) |
| Week 96 + 6 months | 98.9 (96.5 to 99.6) | 97.4 (94.5 to 98.7) |
| Week 96 + 12 months | 95.6 (91.7 to 97.7) | 94.1 (90.2 to 96.5) |
| Week 96 + 18 months | 90.6 (84.9 to 94.2) | 89.5 (84.3 to 93.0) |
| Week 96 + 24 months | 87.1 (79.8 to 91.8) | 86.4 (80.0 to 90.9) |
| Week 96 + 30 months | 84.8 (75.8 to 90.6) | 79.1 (68.9 to 86.3) |
| Week 96 + 36 months | 84.8 (75.8 to 90.6) | — |
The immunologic change was determined by Cluster of CD4+ cell count. CD4+ cell count post-Week 96 to end of extension were assessed.
| cells/mm^3 | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Week 96 + 6 months | 790.2 ± 17.23 | 749.7 ± 16.44 |
| Week 96 + 12 months | 779.4 ± 22.45 | 774.3 ± 21.91 |
| Week 96 + 18 months | 789.8 ± 23.43 | 758.4 ± 23.25 |
| Week 96 + 24 months | 781.9 ± 37.77 | 784.1 ± 30.78 |
| Week 96 + 30 months | 741.6 ± 37.12 | 736.7 ± 37.47 |
| Week 96 + 36 months | 784.7 ± 69.74 | 778.4 ± 86.59 |
Number of participants with DRV, FTC, TDF/TAF resistance were reported.
| Participants | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | Switch to D/C/F/TAF |
|---|---|---|---|
| DRV resistance-associated mutations (RAMs) | 0 | 0 | 0 |
| TFV RAMs | 0 | 0 | 0 |
| FTC RAMs | 2 | 1 | 2 |
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
| percentage of participants | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | Switch to D/C/F/TAF |
|---|---|---|
| Grade 3 AEs | 3.5 | 5.2 |
| Grade 4 AEs | 0 | 1.3 |
| SAEs | 3.2 | 4.8 |
| Premature discontinuations due to AEs | 1.0 | 1.3 |
Collected over Up to 60 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| D/C/F/TAF+ FTC/TDF (Test) | 0/362 (0%) | 47/362 (13%) | 284/362 (78.5%) |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 1/363 (0.3%) | 36/363 (9.9%) | 252/363 (69.4%) |
| Switch to D/C/F/TAF Group | 1/322 (0.3%) | 21/322 (6.5%) | 137/322 (42.5%) |
| Event | D/C/F/TAF+ FTC/TDF (Test) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | Switch to D/C/F/TAF Group |
|---|---|---|---|
| AppendicitisInfections and infestations | 3/362 | 2/363 | 1/322 |
| Hepatitis AInfections and infestations | 3/362 | 3/363 | 2/322 |
| PneumoniaInfections and infestations | 3/362 | 1/363 | 0/322 |
| Suicide AttemptPsychiatric disorders | 0/362 | 3/363 | 1/322 |
| ErysipelasInfections and infestations | 0/362 | 0/363 | 2/322 |
| Suicidal IdeationPsychiatric disorders | 1/362 | 1/363 | 2/322 |
| Anogenital DysplasiaGastrointestinal disorders | 2/362 | 1/363 | 0/322 |
| Anal AbscessInfections and infestations | 2/362 | 1/363 | 0/322 |
| Anogenital WartsNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/362 | 2/363 | 0/322 |
| RashSkin and subcutaneous tissue disorders | 0/362 | 2/363 | 0/322 |
| Event | D/C/F/TAF+ FTC/TDF (Test) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | Switch to D/C/F/TAF Group |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 89/362 | 72/363 | 18/322 |
| NasopharyngitisInfections and infestations | 64/362 | 38/363 | 19/322 |
| HeadacheNervous system disorders | 56/362 | 38/363 | 11/322 |
| NauseaGastrointestinal disorders | 34/362 | 46/363 | 8/322 |
| SyphilisInfections and infestations | 41/362 | 25/363 | 24/322 |
| Upper Respiratory Tract InfectionInfections and infestations | 40/362 | 30/363 | 26/322 |
| RashSkin and subcutaneous tissue disorders | 37/362 | 25/363 | 9/322 |
| PharyngitisInfections and infestations | 31/362 | 19/363 | 7/322 |
| Back PainMusculoskeletal and connective tissue disorders | 31/362 | 10/363 | 16/322 |
| OsteopeniaMusculoskeletal and connective tissue disorders | 19/362 | 29/363 | 0/322 |
The intent-to-treat (ITT) analysis set included all the participants who were randomized and received at least one dose of study treatment in the study.
| Age, Continuous(years) | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | Total |
|---|---|---|---|
| Median | 34 (19 to 61) | 34 (18 to 71) | 34.0 (18 to 71) |
| Age, Customized(Participants) | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | Total |
|---|---|---|---|
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 362 | 362 | 724 |
| From 65 to 84 years | 0 | 1 | 1 |
| 85 years and over | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | Total |
|---|---|---|---|
| Female | 44 | 41 | 85 |
| Male | 318 | 322 | 640 |
| Race/Ethnicity, Customized(Participants) | D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | Total |
|---|---|---|---|
| Asian | 4 | 7 | 11 |
| Black or African American | 40 | 40 | 80 |
| Hispanic or Latino | 41 | 38 | 79 |
| Other | 19 | 18 | 37 |
| White Non-Hispanic | 258 | 260 | 518 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2015 to primary completion in Mar 2017, 19 months.
Results were first posted in Sep 2018, 1 year 6 months after primary completion. A results delay was requested in Mar 2018.
Of 34 industry-sponsored phase 3 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 27. This study's 19 months is below that.
Counting every sponsor, half of 65 studies reached it within 26 months; a quarter within 19 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Darunavir · Cobicistat · Emtricitabine · Tenofovir alafenamide
Acquired Immunodeficiency Syndrome →